On June 3, 2026, SEBI issued a 109-page interim order barring Rajesh Exports CMD Rajesh Mehta from trading in company securities for 3 years, alleging 99.8% of its consolidated revenues, totalling ₹15.15 lakh crore, were fictitious. The same session saw SoftBank offload a ₹2,873 crore Lenskart stake, Tata Motors quietly ditch JLR’s EMA platform for Avinya, Suzlon unveil a full-stack renewable pivot, and Aurobindo Pharma absorb a second Eugia FDA flag in six months. Sensex closed down ~330 points at approximately 74,414; Nifty held above 23,400.
Market Snapshot — June 3, 2026
| Index / Sector | Close / Change |
|---|---|
| Sensex | 74,346.17 (-303.67 pts, -0.41%) |
| Nifty 50 | 23,405.60 (-77.95 pts, -0.33%) |
| Nifty IT | -5.57% |
| Nifty PSU Bank | +1.7% to +1.8% |
| Nifty Bank | Highly volatile; recovered sharply from intraday lows |
1. Rajesh Exports — SEBI Drops India’s Biggest Revenue Inflation Allegation
What Happened
- SEBI passed an interim ex-parte order on June 3, 2026, against Rajesh Exports Limited (REL) and its CMD Rajesh Mehta.
- Mehta is barred from dealing in REL securities for 3 years pending investigation completion.
- A new forensic auditor has been ordered; REL must submit required documents within 30 days.
The Numbers SEBI Alleges
| Allegation | Amount |
|---|---|
| Consolidated revenue misrepresented (FY21–FY25) | ₹15.15 lakh crore |
| % of total consolidated revenue that is alleged as fictitious | 99.8% |
| Standalone non-genuine sales recorded (FY22–FY24) | ₹11,487 crore |
| Standalone non-genuine purchases recorded (FY22–FY24) | ₹11,488 crore |
| Company funds routed to Mehta’s personal accounts | ₹339 crore |
| Total funds routed without board/audit approval | ₹926 crore |
| Shareholder wealth erosion estimated by SEBI | ₹1,272.6 crore |
Key Violations Flagged
- 97–99% of REL’s consolidated revenue came from overseas subsidiaries, primarily Switzerland-based Valcambi SA, but Valcambi reported minimal standalone revenues in its own audited financials.
- REL recorded ₹11,487 crore in sales and ₹11,488 crore in purchases with stockbroker Affluence Shares & Stocks, but Affluence denied any such transactions occurred.
- SEBI says these were non-genuine entries linked directly to Mehta’s personal derivative trades, used to inflate turnover without real economic activity.
- Company funds were transferred to Mehta’s personal account for derivative trading without board approval, audit committee knowledge, or related-party disclosures.
- REL allegedly impeded the investigation by failing to furnish consolidated-level information and making inconsistent submissions at different probe stages.
What SEBI’s WTM Said
“The aberrations prima facie noted in the matter, where approximately 97–99% of the company’s revenue is inflated, are egregious and unheard of.” — SEBI Whole Time Member Kamlesh Chandra Varshney, Interim Order, June 3, 2026
Stock Context
- REL stock was trading around ₹118 before the order; the 52-week range is ₹80.38–₹237.88.
- The stock has delivered a 1-year return of -40.93% vs Nifty 50’s -5.18% over the same period.
- LIC holds approximately 10% stake in REL, making it the largest institutional shareholder caught in the crossfire.
- This is an interim order, formal hearing will follow. The company has not yet responded publicly.
2. Lenskart—SoftBank Books ₹2,873 Crore in Block Deal
What Happened
- On June 3, SoftBank — via its affiliate SVF II Lightbulb (Cayman) — sold a 3.25% stake in Lenskart Solutions via NSE block deal.
- 56.5 million shares sold at ₹508.55 per share.
- Deal executed at a ~3% discount to Tuesday’s closing price.
Deal Snapshot
| Parameter | Detail |
|---|---|
| Shares offloaded | 5.65 crore |
| Price per share | ₹508.55 |
| Total deal size | ₹2,873 crore (~$300.2 million) |
| Discount to previous close | ~3% |
| SoftBank stake pre-deal (March-end) | 13.13% |
| SoftBank stake post-deal | ~9.88% (approx.) |
| SoftBank return on original 2019 investment | 5.4x |
Who Bought
- Fidelity
- Los Angeles City Employees’ Retirement System (LACERS)
- ICICI Prudential Mutual Fund
- Kotak Mahindra Mutual Fund
Strong institutional demand at a 3% discount, buyers were not chasing; they were placed.
The Tension Investors Are Missing
Lenskart’s Q4 FY26 (March quarter) showed revenue of ₹2,516 crore — up 46% YoY. But net profit fell ~9% in the same quarter. Revenue is scaling fast; margins are not. That gap is the real story behind why SoftBank is trimming, not exiting.
SoftBank’s Lenskart Journey
| Milestone | Detail |
|---|---|
| First investment | December 2019 — led $275 million round |
| Pre-IPO stake | 15.03% (25.34 crore shares) |
| Shares sold at IPO (price ₹402) | 2.55 crore shares / ₹1,025 crore |
| Lenskart performance since IPO listing | +28.4% from issue price |
| Current market cap | ~₹89,651 crore ($9.4 billion) |
3. Tata Motors — Avinya Drops JLR’s EMA, Switches to Chery-JLR Freelander Platform
What Happened
- Tata Motors has confirmed the first Avinya vehicle, the Avinya X (codenamed P2), will use the Freelander platform produced by Chery-JLR (CJLR), not JLR’s EMA (Electrified Modular Architecture) as originally planned.
- Engineering prototypes are expected later in 2026; market launch is now targeted for early/mid 2027.
- The P1 (originally slated as the first Avinya) has been deprioritised; Avinya X leads the roadmap.
Why the Platform Pivot
| Factor | Detail |
|---|---|
| Original platform | JLR EMA |
| New platform | Chery-JLR Freelander EV |
| Reason for switch | EMA economics “difficult to justify” for Avinya’s intended price positioning and volumes |
| Production location | Tata PEML + JLR’s Panapakkam facility, Tamil Nadu |
| Engineering adaptation | Tata Technologies teams in China + India + UK reworking electronics, software, vehicle systems for Indian requirements |
| Battery strategy | 65–80 kWh packs (from Agratas initially, subject to scale-up) |
What This Means
- Tata currently holds ~40% market share in India’s passenger EV segment. The Avinya X was positioned as its premium EV firewall against competition from MG, BYD, and Mahindra’s BE/XEV range in the ₹40–50 lakh bracket.
- A platform switch is not unusual in global EV development, but a 12–18 month timeline slip in a fast-moving EV market has strategic costs.
- Tata’s ongoing launches (Sierra EV, Safari EV, Tiago/Punch EV facelifts) cover the volume end; Avinya X is meant to defend the premium flank. That flank now opens later.
4. Suzlon Energy — Suzlon 2.0: From Wind OEM to Full-Stack Renewable Play
What Happened
- On June 3, Suzlon unveiled “Suzlon 2.0,” a strategic overhaul positioning it as a wind-first, full-stack renewable energy solutions company.
- Target: 70 GW assets under management by FY31, a 4x increase from current levels.
- Target: 10 GW annual renewable energy sales by FY31.
Suzlon 2.0 — The Four Business Pillars
| Business Arm | Description |
|---|---|
| Wind-First Full Stack RE Tech Solutions | Wind turbine supply + integration |
| RE DevCo | India’s first integrated co-development platform — converts renewable potential to execution-ready sites |
| RE Projects | EPC-style renewable project delivery |
| RE Asset Management | Wind, solar, hybrid, multi-brand portfolios; target 70 GW AUM by FY31 |
Battery Storage Entry — Key Details
- Suzlon is entering the intelligent BESS (Battery Energy Storage System) segment.
- BESS product portfolio will range from 2 MW to 6+ MW systems.
- A dedicated BESS manufacturing facility planned by 2027, tailored to Indian grid conditions.
- Purpose: Making renewable energy dispatchable and grid-ready — solving the intermittency problem that pure wind/solar cannot address alone.
What Suzlon Is NOT Doing
- Suzlon Vice-Chairman Girish Tanti confirmed the company will not enter solar manufacturing. Reason: excess global capacity, especially from China. Suzlon’s role will be that of an integrator, not a panel producer.
- This is strategically significant: Suzlon sidesteps the commodity trap that has crushed solar margins globally and instead positions itself to capture value at the project and services layer.
Wind Ambitions
- Target: Maintain 40% market share in Indian wind.
- Target: 3 GW of export order intake by FY31.
- New turbine platforms: S175 (5 MW) and S163 (6.3 MW) under the BlueSky product range.
5. Aurobindo Pharma — Second Eugia Unit Gets FDA OAI in 6 Months
What Happened
- The US FDA has classified Eugia Pharma Specialities Unit-I (formulation manufacturing, Shameerpet, Telangana) as “Official Action Indicated” (OAI).
- Inspection was conducted: February 16–27, 2026; 4 observations issued.
- Formal OAI communication received by Aurobindo: May 23, 2026.
- Aurobindo says: no impact on financials or operations at this stage.
The Pattern Investors Must Track
| Event | Facility | Date | Observations | Current Status |
|---|---|---|---|---|
| OAI #1 | Eugia Unit-II, Bhiwadi, Rajasthan | Nov 3–14, 2025 | 9 | OAI |
| OAI #2 | Eugia Unit-I, Shameerpet, Telangana | Feb 16–27, 2026 | 4 | OAI |
| Precedent | Eugia Unit-III | May 2024 → Aug 2024 | — | OAI → Warning Letter (3 months) |
Two different Eugia facilities flagged within six months. Eugia Unit-III went from OAI to Warning Letter in approximately 3 months in 2024, and the stock fell 6% on that disclosure. The market has not yet priced the Unit-I/Unit-II pattern similarly.
Q4 FY26 Context
- Consolidated revenue: ₹8,853 crore (up 5.6% YoY)
- Net profit: ₹921 crore (up 2% YoY)
- Europe revenues: ₹2,795 crore (up 30.2% YoY); crossed €1 billion annual milestone in FY26
- The Eugia OAI facilities are formulation units. Aurobindo’s US revenue remains its largest geography. The specific ANDA-approved products manufactured at Eugia Unit-I (Telangana) have not been publicly disclosed, but the facility’s OAI classification signals regulatory follow-up actions are likely.
Key Trigger Watch — What’s Next
| Company | Next Trigger | Timeline |
|---|---|---|
| Rajesh Exports | Forensic auditor appointment + document submission to SEBI | Within 30 days |
| Lenskart | Q1 FY27 results — margin trajectory post SoftBank block deal | July 2026 |
| Tata Motors | Avinya X engineering prototype reveal | Late 2026 |
| Suzlon | BESS manufacturing facility announcement; FY27 order intake data | FY27 Q1–Q2 |
| Aurobindo Pharma | FDA response to Eugia Unit-I OAI; potential Warning Letter | 30–90 days |
Check live:
Frequently Asked Questions
Q1: What happens next in the Rajesh Exports SEBI case, can trading be suspended?
The June 3 order is interim and ex-parte, meaning Rajesh Exports has not yet presented its defence. SEBI has directed REL to appoint a new forensic auditor and submit documents within 30 days. In early 2026, NSE had already warned of potential trading suspension over non-compliance in shareholding pattern disclosures. If REL fails to cooperate with the ongoing investigation, suspension risk increases. Promoter Rajesh Mehta is already barred from dealing in REL securities for 3 years. A formal hearing is the next procedural step.
Q2: Is SoftBank exiting Lenskart completely after Wednesday’s block deal?
No. SoftBank held 13.13% as of March-end 2026. After selling a 3.25% stake on June 3, it retains approximately 9.88%. SoftBank originally invested in December 2019 at the $275 million round. It also sold 2.55 crore shares at the IPO price of ₹402, netting ₹1,025 crore. Wednesday’s deal adds ₹2,873 crore to that exit tally; total realised returns are now well above 5x. The remaining ~10% stake is a hold, not an exit signal.
Q3: Should investors be worried about Aurobindo Pharma’s back-to-back Eugia FDA OAI classifications?
The precedent from Eugia Unit-III is instructive, OAI in May 2024 became a Warning Letter by August 2024, approximately 3 months later, and the stock fell ~6% on that event. Two facilities (Unit-I Telangana and Unit-II Rajasthan) now carry OAI status within a 6-month window. Aurobindo’s Q4 FY26 net profit was ₹921 crore, with Europe revenues up 30.2%, the financials are healthy. But if either OAI escalates to a Warning Letter, US supply impact and stock pressure would follow. Watch the 30-day remediation window on Unit-I.
All financial data sourced from SEBI enforcement orders, NSE block deal disclosures, Reuters, Business Standard, Autocar India, and company exchange filings as of June 3–4, 2026.
